Development
Vera Therapeutics, Inc.
VERA
$19.25
-$1.39-6.73%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 0.29% | 32.95% | 7.31% | -31.44% | -66.15% |
| Total Depreciation and Amortization | -48.51% | -91.90% | 15.24% | -292.76% | -43.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.47% | 0.86% | -2.73% | -51.45% | 120.46% |
| Change in Net Operating Assets | -5,813.95% | -91.70% | -87.86% | 1,935.70% | 93.54% |
| Cash from Operations | -29.27% | 32.41% | -24.24% | -14.89% | 3.22% |
| Capital Expenditure | -- | -- | -- | 100.00% | -533.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 118.77% | -806.63% | -8.95% | 659.41% | 94.29% |
| Cash from Investing | 118.77% | -806.63% | -8.95% | 650.70% | 94.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -31.25% | -99.63% | 13,851.57% | -15.37% | 1,933.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -10,929.85% | 198.53% | -- |
| Cash from Financing | -31.25% | -99.60% | 421.44% | 2,180.73% | 1,791.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.79% | -210.50% | 623.40% | 165.08% | 67.33% |